Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907290 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
A Phase 2 study of Chronic Hepatitis D Infection, sponsored by Mirum Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06907290 is a Phase 2 study of Chronic Hepatitis D Infection that is active but no longer recruiting, run by Mirum Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06907290, a Phase 2 study of Chronic Hepatitis D Infection, is active but no longer recruiting, sponsored by Mirum Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.
Conditions Studied
Interventions
- DRUG Brelovitug 300 mg
- DRUG Brelovitug 900 mg
- DRUG Delayed Treatment with Brelovitug 300mg
Study Locations (20)
California
- 247 Garden Grove - Garden Grove
- 242 Huntington Beach - Huntington Beach
- 252 Long Beach - Long Beach
- 244 Los Angeles - Los Angeles
New York
- 245 New York - New York
- 256 New York - New York
- 253 New York - New York
- 255 New York - New York
Other
- 101 Camperdown - Camperdown
- 104 Liverpool - Liverpool
- 705 Plovdiv - Plovdiv
Florida
- 250 Miami - Miami
Illinois
- 251, Illinois - Chicago
Iowa
- 248 Lowa - Cities in Iowa
Maryland
- 254 Baltimore - Baltimore
Massachusetts
- 241, Massachusetts - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06907290
The ClinicalTrials.gov registry entry for NCT06907290 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis D Infection appearing as the primary indexed condition, and to 3 interventions - of which Brelovitug 300 mg is the first listed.
NCT06907290 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Other.
Frequently Asked Questions
What is clinical trial NCT06907290 about?
NCT06907290 is a clinical study titled "A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection". This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participa...
What is the current status of trial NCT06907290?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-03-25. Estimated completion is 2029-09.
What conditions does trial NCT06907290 study?
This clinical trial studies the following conditions: Chronic Hepatitis D Infection.
What interventions are being tested in trial NCT06907290?
The interventions under investigation include: Brelovitug 300 mg (DRUG), Brelovitug 900 mg (DRUG), Delayed Treatment with Brelovitug 300mg (DRUG).
Who is sponsoring clinical trial NCT06907290?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907290 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis D Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.